Efficacy and safety of regdanvimab in patients with mild/moderate COVID-19 and high risk of progression of the disease: a retrospective study in a short-term stay unit - PDF (Russian)

Address of the Editorial Office:

• Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

• Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

• Tel.: +7 (926) 905-41-26
• E-mail: e.gorbacheva@ter-arkhiv.ru